CO5200769A1 - Los inhibidores triciclicos de poli (adp-ribosa) polimerasas - Google Patents
Los inhibidores triciclicos de poli (adp-ribosa) polimerasasInfo
- Publication number
- CO5200769A1 CO5200769A1 CO00065062A CO00065062A CO5200769A1 CO 5200769 A1 CO5200769 A1 CO 5200769A1 CO 00065062 A CO00065062 A CO 00065062A CO 00065062 A CO00065062 A CO 00065062A CO 5200769 A1 CO5200769 A1 CO 5200769A1
- Authority
- CO
- Colombia
- Prior art keywords
- aryl
- heterocycloalkyl
- alkynyl
- cycloalkyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de la fórmula :<EMI FILE="00065062_1" ID="1" IMF=JPEG >en donde:X es O u S;Y es N o CR3, donde R3 es: H; halógeno; ciano; un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo; heterocycloalquilo, arilo, o grupo heteroarilo, o -C(W)-R20, donde W es O u S, y R20 es: H; OH; un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, O-alquilo, o grupo O-arilo; o NR27R28, donde R27 y R28 son cada uno independientemente H, OH, o un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo;-CR29=N-R30, donde R29 es H o un amino sustituido opcionalmente, alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo o grupo heteroarilo; y R30 es H, OH, un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, O-alquil, o grupo O-arilo, o NR31R32, donde R31 y R32 son cada uno independientemente H, OH, o un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo;R1 es H,halógeno;ciano;un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo; C(O)R12, donde R12 es: H; un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo; o OR19 o NR21R22, donde R19, R21 y R22 son cada uno independientemente H o un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo;OR13, donde R13 es H o un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo;S(O)nR16, donde n es 0, 1 o 2, y R16 es: H; un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicIoalquilo, heterocicloalquilo, arilo, o grupo heteroarilo; o NR23R24, donde R23 y R24 son cada uno independientemente H o un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo; o NR17R18, donde R17 y R18 son cada uno independientemente H; un alquilo sustituido opcionalmente, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, o grupo heteroarilo; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15214299P | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5200769A1 true CO5200769A1 (es) | 2002-09-27 |
Family
ID=22541675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00065062A CO5200769A1 (es) | 1999-08-31 | 2000-08-30 | Los inhibidores triciclicos de poli (adp-ribosa) polimerasas |
Country Status (48)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19946289A1 (de) * | 1999-09-28 | 2001-03-29 | Basf Ag | Benzodiazepin-Derivate, deren Herstellung und Anwendung |
| TR200101499T1 (tr) * | 1999-09-28 | 2002-09-23 | Basf Aktiengesellschaft | Azepinoindol türevleri, hazırlanmaları ve kullanımları. |
| DE10021468A1 (de) * | 2000-05-04 | 2001-11-08 | Basf Ag | Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| FR2816942B1 (fr) * | 2000-11-23 | 2003-05-09 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| AU2002358650A1 (en) * | 2001-12-14 | 2003-06-30 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| US7026311B2 (en) * | 2002-01-10 | 2006-04-11 | Abbott Gmbh & Co., Kg | Dibenzodiazepine derivatives, their preparation and use |
| AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003103666A2 (en) * | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| JP3990718B2 (ja) | 2003-01-09 | 2007-10-17 | ファイザー・インク | キナーゼ阻害剤としてのジアゼピノインドール誘導体 |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| KR101138471B1 (ko) * | 2003-07-25 | 2012-04-25 | 화이자 인코포레이티드 | 트리시클로 ｐａｒｐ 저해제 |
| WO2005035534A1 (ja) * | 2003-10-08 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 |
| DK1684736T3 (da) | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | Inhibitorer af DNA-skadereparation til behandling af cancer |
| BRPI0515255A (pt) * | 2004-09-22 | 2008-07-15 | Pfizer | método para preparar inibidores de poli(adp-ribose) polimerases |
| AU2006206512B2 (en) * | 2005-01-19 | 2012-09-13 | Eisai Inc. | Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP |
| AR053902A1 (es) | 2005-06-14 | 2007-05-23 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos macrociclicos |
| US20090226412A1 (en) | 2005-06-24 | 2009-09-10 | Ono Pharmaceutical Co., Ltd., | Agent for reduction of bleeding in cerebrovascular disorder |
| CN101242822B (zh) * | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
| WO2007018998A2 (en) * | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | 癌の治療法 |
| CN101534836B (zh) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| KR20100038295A (ko) | 2007-06-05 | 2010-04-14 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘 |
| WO2008154129A1 (en) * | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
| WO2009064738A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| WO2009073869A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| LT2346495T (lt) | 2008-10-07 | 2016-10-10 | Astrazeneca Uk Limited | Farmacinė kompozicija 514 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| JP2015533783A (ja) * | 2012-09-05 | 2015-11-26 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 非生物的な植物ストレスに対する活性物質としてのベンゾジアゼピノン類及びベンゾアゼピノン類又はそれらの塩の使用 |
| EP3424909A1 (en) * | 2014-01-05 | 2019-01-09 | Washington University | A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor |
| KR101896567B1 (ko) | 2015-07-23 | 2018-09-07 | 인스티튜트 큐리 | 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| MA46779A (fr) | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| TWI820077B (zh) | 2018-01-05 | 2023-11-01 | 美商斯布雷克薩一號公司 | 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法 |
| US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| KR20210025016A (ko) * | 2018-06-28 | 2021-03-08 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도 |
| US20240287093A1 (en) * | 2018-08-24 | 2024-08-29 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| CN113195473B (zh) * | 2018-12-14 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 三环化合物作为sting激动剂及其制备方法和医药用途 |
| US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| EP3996749A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2023524212A (ja) | 2020-04-28 | 2023-06-09 | ライゼン ファーマシューティカルズ アーゲー | ポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤として有用な新規化合物 |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| WO2022150596A1 (en) | 2021-01-08 | 2022-07-14 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
| WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1052390A (es) | 1964-03-24 | |||
| US3734919A (en) * | 1969-11-03 | 1973-05-22 | Upjohn Co | 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones |
| US3642820A (en) * | 1969-11-03 | 1972-02-15 | Upjohn Co | 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines |
| DE2056215A1 (de) | 1970-11-16 | 1972-05-18 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen |
| US3883590A (en) | 1971-06-01 | 1975-05-13 | Universal Oil Prod Co | Preparation of n-alkylarylcarboxamides |
| US3900477A (en) | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
| US3950343A (en) | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
| US3978066A (en) | 1973-11-06 | 1976-08-31 | Ayerst, Mckenna And Harrison Ltd. | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives |
| JPS57144286A (en) | 1981-03-02 | 1982-09-06 | Takeda Chem Ind Ltd | Azepinoindole derivative and its preparation |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE4125292A1 (de) | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5342946A (en) | 1992-12-02 | 1994-08-30 | Guilford Pharmaceuticals Inc. | Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors |
| WO1995009159A1 (en) | 1993-09-28 | 1995-04-06 | Otsuka Pharmaceutical Company, Limited | Quinoxaline derivative as antidiabetic agent |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5561161A (en) | 1994-03-25 | 1996-10-01 | Oxigene, Inc. | Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof |
| US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| ES2105959B1 (es) | 1995-01-17 | 1998-07-01 | Zeneca Pharma Sa | Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion. |
| US5659082A (en) | 1995-04-03 | 1997-08-19 | Centaur Pharmaceuticals, Inc. | Nitro- and aminobenzamide compounds for neurodegenerative disorders |
| US5756548A (en) | 1995-04-03 | 1998-05-26 | Centaur Pharmaceuticals, Inc. | Acetamidobenzamide compounds for neurodegenerative disorders |
| CZ30398A3 (cs) * | 1995-08-02 | 1998-06-17 | Newcastle University Ventures Limited | Benzimidazolové sloučeniny, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako chemoterapeutických činidel |
| HUT76302A (en) | 1995-11-30 | 1997-07-28 | Chinoin Gyogyszer Es Vegyeszet | Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| IL132758A0 (en) | 1997-05-13 | 2001-03-19 | Octamer Inc | Methods for treating inflammation and inflammatory diseases using padprt |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| WO1999011622A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| EP1077946A1 (en) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
-
2000
- 2000-08-29 EC EC2000003637A patent/ECSP003637A/es unknown
- 2000-08-30 GT GT200000145A patent/GT200000145A/es unknown
- 2000-08-30 CO CO00065062A patent/CO5200769A1/es not_active Application Discontinuation
- 2000-08-30 MY MYPI20004039A patent/MY135910A/en unknown
- 2000-08-31 US US09/653,184 patent/US6548494B1/en not_active Expired - Lifetime
- 2000-08-31 CA CA002382404A patent/CA2382404C/en not_active Expired - Fee Related
- 2000-08-31 SI SI200030643T patent/SI1208104T1/xx unknown
- 2000-08-31 EE EEP200200100A patent/EE200200100A/xx unknown
- 2000-08-31 AU AU73389/00A patent/AU781826B2/en not_active Ceased
- 2000-08-31 UA UA2002042574A patent/UA73144C2/uk unknown
- 2000-08-31 EP EP00961437A patent/EP1208104B1/en not_active Expired - Lifetime
- 2000-08-31 PA PA20008501801A patent/PA8501801A1/es unknown
- 2000-08-31 GE GEAP20006389A patent/GEP20043268B/en unknown
- 2000-08-31 PE PE2000000896A patent/PE20010538A1/es not_active Application Discontinuation
- 2000-08-31 DE DE60017575T patent/DE60017575T2/de not_active Expired - Lifetime
- 2000-08-31 OA OA1200200064A patent/OA12016A/en unknown
- 2000-08-31 KR KR1020027002629A patent/KR20020038742A/ko active IP Right Grant
- 2000-08-31 MX MXPA02002138A patent/MXPA02002138A/es active IP Right Grant
- 2000-08-31 BR BR0015051-7A patent/BR0015051A/pt not_active Application Discontinuation
- 2000-08-31 SK SK259-2002A patent/SK2592002A3/sk unknown
- 2000-08-31 CN CN00815066A patent/CN1384835A/zh active Pending
- 2000-08-31 IL IL14786300A patent/IL147863A0/xx unknown
- 2000-08-31 PL PL00354242A patent/PL354242A1/xx not_active Application Discontinuation
- 2000-08-31 DK DK00961437T patent/DK1208104T3/da active
- 2000-08-31 UY UY26323A patent/UY26323A1/es not_active Application Discontinuation
- 2000-08-31 NZ NZ516793A patent/NZ516793A/en unknown
- 2000-08-31 ES ES00961437T patent/ES2234657T3/es not_active Expired - Lifetime
- 2000-08-31 AR ARP000104549A patent/AR035162A1/es unknown
- 2000-08-31 YU YU15102A patent/YU15102A/sh unknown
- 2000-08-31 DZ DZ003216A patent/DZ3216A1/fr active
- 2000-08-31 WO PCT/US2000/023882 patent/WO2001016136A2/en active IP Right Grant
- 2000-08-31 EA EA200200306A patent/EA200200306A1/ru unknown
- 2000-08-31 JP JP2001519702A patent/JP4272375B2/ja not_active Expired - Lifetime
- 2000-08-31 HU HU0202703A patent/HUP0202703A3/hu unknown
- 2000-08-31 PT PT00961437T patent/PT1208104E/pt unknown
- 2000-08-31 AP APAP/P/2002/002449A patent/AP1553A/en active
- 2000-08-31 AT AT00961437T patent/ATE287406T1/de not_active IP Right Cessation
- 2000-08-31 SV SV2000000162A patent/SV2003000162A/es unknown
- 2000-08-31 CZ CZ2002613A patent/CZ2002613A3/cs unknown
- 2000-09-20 DO DO2000000069A patent/DOP2000000069A/es unknown
-
2002
- 2002-01-28 NO NO20020421A patent/NO322475B1/no unknown
- 2002-01-30 ZA ZA200200830A patent/ZA200200830B/en unknown
- 2002-02-01 CR CR6577A patent/CR6577A/es not_active Application Discontinuation
- 2002-02-27 IS IS6289A patent/IS6289A/is unknown
- 2002-03-29 BG BG106562A patent/BG106562A/bg unknown
- 2002-03-29 HR HR20020271A patent/HRP20020271A2/hr not_active Application Discontinuation
- 2002-03-29 MA MA26577A patent/MA25876A1/fr unknown
- 2002-09-25 HK HK02106977.2A patent/HK1045509B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200769A1 (es) | Los inhibidores triciclicos de poli (adp-ribosa) polimerasas | |
| CO5261497A1 (es) | Gama-hidroxi-2-(fluoroalquilamino-carbonil)-1-piperazino pentanamidas y sus usos | |
| CO5170518A1 (es) | Compuestos n-(benzocicloalquilo) derivados de amino aralifaticos | |
| CO5180568A1 (es) | Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen | |
| CO5160302A1 (es) | INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO | |
| WO2002079146A3 (en) | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| CO5140093A1 (es) | Epotilonas c 21 modificadas | |
| CO5130017A1 (es) | Derivados de quinolin-2-ona alquinil sustituidos utiles como agentes anticancerosos | |
| PE20060197A1 (es) | Heterociclos biciclicos como inhibidores de cinasa | |
| PE20040934A1 (es) | Derivados de pirimidina como inhibidores selectivos de tirosina quinasas | |
| DE60208808D1 (de) | Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge | |
| CO5261539A1 (es) | Compuestos farmaceuticamente activos | |
| ATE260103T1 (de) | Ortho-anthranilamide derivate als antikoagulantien | |
| CO5150150A1 (es) | 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales | |
| CO5271690A1 (es) | Derivados de pirimidina | |
| CO5590960A2 (es) | Derivados de azaindolilalquilamina como ligandos de 5- hidroxitriptamina-6 | |
| AR007128A1 (es) | Un compuesto antipicornaviral, composicion farmaceutica que lo contiene y metodos para preparar a dicho compuesto | |
| PE20011066A1 (es) | PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| ATE556067T1 (de) | Modulatoren des vanilloid rezeptors | |
| CO5210890A1 (es) | Compuestos quimicos del tipo benzodia - o tiazoles y su proceso de obtencion | |
| PE20021074A1 (es) | Derivados de n-oxiantranilamida y los medicamentos que los contienen | |
| CY1105837T1 (el) | Hmi - συνθεση απο paclitaxel με χρησιμοποιηση διαλκυλδιχλωροσιλανιων | |
| ECSP045309A (es) | Derivados de fenil amidas con silicio útiles como microbiocidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |